journal article·2024-03-05

Logic “AND Gate Circuit”-Based Gasdermin Protein Expressing Nanoplatform Induces Tumor-Specific Pyroptosis to Enhance Cancer Immunotherapy

Xiaoxi Wang, Wenyan Zhang, Yan Wang, Xueqin Zhu, Zimai Liu, Meiyi Liu, Zixian Wu, Bingyu Li, Sijia Liu, Shixin Liao, Pingping Zhu, Benyu Liu, Chong Li, Yongchao Wang, Zhenzhen Chen

ACS Nano· Volume 18· Issue 9
Publisher page

Abstract

Pyroptosis mediated by gasdermin protein has shown great potential in cancer immunotherapies. However, the low expression of gasdermin proteins and the systemic toxicity of nonspecific pyroptosis limit its clinical application. Here, we designed a synthetic biology strategy to construct a tumor-specific pyroptosis-inducing nanoplatform M-CNP/Mn@pPHS, in which a pyroptosis-inducing plasmid (pPHS) was loaded onto a manganese (Mn)-doped calcium carbonate nanoparticle and wrapped in a tumor-derived cell membrane. M-CNP/Mn@pPHS showed an efficient tumor targeting ability. After its internalization by tumor cells, the degradation of M-CNP/Mn@pPHS in the acidic endosomal environment allowed the efficient endosomal escape of plasmid pPHS. To trigger tumor-specific pyroptosis, pPHS was designed according to the logic “AND gate circuit” strategy, with Hif-1α and Sox4 as two input signals and gasdermin D induced pyroptosis as output signal. Only in cells with high expression of Hif-1α and Sox4 simultaneously will the output signal gasdermin D be expressed. Since Hif-1α and Sox4 are both specifically expressed in tumor cells, M-CNP/Mn@pPHS induces the tumor-specific expression of gasdermin D and thus pyroptosis, triggering an efficient immune response with little systemic toxicity. The Mn 2+ released from the nanoplatform further enhanced the antitumor immune response by stimulating the cGAS-STING pathway. Thus, M-CNP/Mn@pPHS efficiently inhibited tumor growth with 79.8% tumor regression in vivo . We demonstrate that this logic “AND gate circuit”-based gasdermin nanoplatform is a promising strategy for inducing tumor-specific pyroptosis with little systemic toxicity.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Inflammasome and immune disorders · Toxoplasma gondii Research Studies · interferon and immune responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China

Center for Stem Cell and Regenerative Medicine, Academy of Medical Sciences, Zhengzhou University, Zhengzhou 450052, China

Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China

Zhongke Jianlan Medical Research Institute, Beijing 100190, China

Henan Key Laboratory of Bioactive Macromolecules, Zhengzhou University, Zhengzhou 450001, China

International Joint Laboratory for Protein and Peptide Drugs of Henan Province, Zhengzhou University, Zhengzhou 450001, China

Funding

National Natural Science Foundation of China · Start-up Grant from Zhengzhou University · Postdoctoral Science Foundation of China · Joint Funding of Henan Provincial Science and Technology R&D Plan

References (42)

Show source-provided references
1. 10.1038/s41423-022-00905-x10.1038/s41423-022-00905-x ↗
2. 10.1016/j.smim.2023.10184110.1016/j.smim.2023.101841 ↗
3. 10.1038/nature2239310.1038/nature22393 ↗
4. 10.1186/s12950-022-00316-910.1186/s12950-022-00316-9 ↗
5. 10.7150/thno.7108610.7150/thno.71086 ↗
6. 10.1016/j.bbadis.2023.16663710.1016/j.bbadis.2023.166637 ↗
7. 10.1021/acsami.2c0057410.1021/acsami.2c00574 ↗
8. 10.1074/jbc.M111.23851910.1074/jbc.M111.238519 ↗
9. 10.1002/ijc.3339010.1002/ijc.33390 ↗
10. 10.1002/cam4.210310.1002/cam4.2103 ↗
11. 10.18632/aging.20397310.18632/aging.203973 ↗
12. 10.1016/j.biomaterials.2012.01.03110.1016/j.biomaterials.2012.01.031 ↗
13. 10.1016/j.cej.2022.13987910.1016/j.cej.2022.139879 ↗
14. 10.1002/adfm.20120221510.1002/adfm.201202215 ↗
15. 10.1039/D2CS00352J10.1039/D2CS00352J ↗
16. 10.1038/s41580-018-0024-z10.1038/s41580-018-0024-z ↗
17. 10.1021/jacs.7b0783110.1021/jacs.7b07831 ↗
18. 10.1021/jacs.0c0131510.1021/jacs.0c01315 ↗
19. 10.1016/j.cell.2016.01.01110.1016/j.cell.2016.01.011 ↗
20. 10.1126/science.aap898710.1126/science.aap8987 ↗
21. 10.1126/science.aat506210.1126/science.aat5062 ↗
22. 10.1016/j.cell.2016.09.01110.1016/j.cell.2016.09.011 ↗
23. 10.1126/science.aay279010.1126/science.aay2790 ↗
24. 10.1038/s41422-023-00828-w10.1038/s41422-023-00828-w ↗
25. 10.1186/s12943-017-0680-110.1186/s12943-017-0680-1 ↗
26. 10.1016/j.jhep.2017.01.00410.1016/j.jhep.2017.01.004 ↗
27. 10.1016/j.immuni.2020.05.00110.1016/j.immuni.2020.05.001 ↗
28. 10.1186/s13046-020-01733-510.1186/s13046-020-01733-5 ↗
29. 10.1016/j.nantod.2022.10140510.1016/j.nantod.2022.101405 ↗
30. 10.1016/j.biomaterials.2023.12233310.1016/j.biomaterials.2023.122333 ↗
31. 10.1016/j.biomaterials.2020.12010610.1016/j.biomaterials.2020.120106 ↗
32. 10.1002/EXP.2022000210.1002/EXP.20220002 ↗
33. 10.1016/j.msec.2016.03.00910.1016/j.msec.2016.03.009 ↗
34. 10.1186/1476-4598-9-15410.1186/1476-4598-9-154 ↗
35. 10.1021/nl500618u10.1021/nl500618u ↗
36. 10.1016/j.cell.2017.09.04910.1016/j.cell.2017.09.049 ↗
37. 10.1186/1476-4598-9-29310.1186/1476-4598-9-293 ↗
38. 10.1186/s13046-020-01806-510.1186/s13046-020-01806-5 ↗
39. 10.1038/nature1554110.1038/nature15541 ↗
40. 10.1021/jacs.3c0123110.1021/jacs.3c01231 ↗
41. 10.1038/s41467-022-34036-810.1038/s41467-022-34036-8 ↗
42. 10.1038/s41586-020-2079-110.1038/s41586-020-2079-1 ↗